ESC 2022 Late-breaker Discussion: The INVICTUS Trial

Подробнее о видео

Watch on Radcliffe Cardiology: *qly8lp*_ga*MTE1NzYxMzg0NC4xNjYxNTg2ODk0*_ga_T874FCJ3LG*MTY2MTY5NTgwMC4xNi4xLjE2NjE2OTcxMjMuMC4wLjA.&utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-6605&utm_content=esc_hvs_karthikeyan

Late-breaker host, Dr Harriette Van Spall(McMaster University, CA) invited Dr Ganesan Karthikeyan (All India Institute of Medical Sciences, IN) to share the latest data from the INVICTUS trial (NCT02832544).

This randomized, open-label, non-inferiority trial compared rivaroxaban (Xarelto, Bayer) versus standard vitamin K antagonists (VKA) (Warfarin) therapy in 4,500 patients diagnosed with rheumatic heart disease.

Recorded on-site at ESC Congress 2022, Barcelona.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.